PLK1 and breast carcinoma: Moreover, in vitro studies in breast cancer cell lines demonstrated that BUB1, like other mitotic regulators such as AurA and Plk1, is involved in the maintenance of CSC and represents a target for developing anti-CSC therapies [30].